ImpriMed unveils cancer treatment forecast technology
ImpriMed, a precision medicine company, announced that it has expanded its services to include human oncology.The aim is to provide drug-response predictions for routine blood cancers such as newly diagnosed multiple myeloma and acute…
Continue Reading